Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: A multicentric retrospective study

Blood (2025) 146 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2025-1018

Published: 2025

Journal Articles

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)

Blood (2025) 146 (Supplement 1): 58.

https://doi.org/10.1182/blood-2025-58

Published: 2025

Journal Articles

Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort

Blood (2025) 146 (Supplement 1): 1853.

https://doi.org/10.1182/blood-2025-1853

Published: 2025

Journal Articles

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry

Blood (2025) 146 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2025-1012

Published: 2025

Journal Articles

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Blood (2025) 146 (Supplement 1): 956.

https://doi.org/10.1182/blood-2025-956

Published: 2025

Journal Articles

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurelien Belot, Emmanuel Bachy, Herve Ghesquieres, François-Xavier Gros, Krimo Bouabdallah, Guillaume Cartron, Roberta Di Blasi, Roch Houot, Cedric Rossi, Amandine Durand, Fabien Le Bras, Corinne Haioun, Thomas Gastinne, Remy Dulery, Pierre Bories, Fabrice Jardin, Blandine Guffroy, Luc-Matthieu Fornecker, Cristina Castilla-Llorente, Gandhi Damaj, Franck Morschhauser, Michael Loschi, Stephanie Guidez, Choquet Sylvain, Aline Schmidt, Laurianne Drieu La Rochelle, Marie-Thérèse Rubio, Sylvain Carras, Jacques-Olivier Bay, Adrien Chauchet, Magalie Joris, Ludovic Fouillet, Laure Lebras, Julie Abraham, Fontanet Bijou, Olivier Hermine, Antoine Bonnet, Justine Decroocq, Sandy Amorim, Nadine Morineau, Pauline Lionne, Sophie Dennetiere, Laura Herbreteau, Bernard Drenou, Launay Vincent, Gaelle Olivier, Gaëlle Labouré, Olivier Fitoussi, Christophe Fruchart, Cecile Leyronnas, Fanny Cherblanc, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2025-2764

Published: 2025

Journal Articles

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2025-2745

Published: 2025

Journal Articles

MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3875.

https://doi.org/10.1182/blood-2025-3875

Published: 2025

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Blood (2025) 146 (Supplement 1): 5490.

https://doi.org/10.1182/blood-2025-5490

Published: 2025

Journal Articles

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 127.

https://doi.org/10.1182/blood-2025-127

Published: 2025

Journal Articles

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Steven Le Gouill, Virginie de Wilde, Toby A. Eyre, Mary B. Callanan, Gandhi Damaj, Alexis Claudel, Adrien Chauchet, Roch Houot, Ronan Le Calloch, Victoria Cacheux, Marc André, Franck Morschhauser, Barbara Burroni, David John Lewis, Benoit Tessoulin, Aurore Touzart

Blood (2024) 144 (Supplement 1): 745.

https://doi.org/10.1182/blood-2024-194357

Published: 2024

Journal Articles

Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry

Blood (2024) 144 (Supplement 1): 528.

https://doi.org/10.1182/blood-2024-208304

Published: 2024

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Blood (2024) 143 (26): 2804–2807.

https://doi.org/10.1182/blood.2024024452

Published: 2024

Includes: Supplemental data

Journal Articles

Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group

Benoit Tessoulin, Julien Depaus, Pierre Feugier, Ludovic Fouillet, Julie Abraham, Sandy Amorin, Fabrice Jardin, Franck Morschhauser, Catherine Thieblemont, François-Xavier Gros, Bertrand Joly, Hacene Zerazhi, Sophie Bernard, Adrien Chauchet, Stéphane Vigouroux, Christophe Bonnet, Sarah Bailly, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 3094.

https://doi.org/10.1182/blood-2023-173265

Published: 2023

Journal Articles

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Eric Durot, Damien Roos-Weil, Adrien Chauchet, Justine Decroocq, Roberta Di Blasi, Thomas Gastinne, Hedi Bensader, Morgane Cheminant, Caroline Jacquet, Stephanie Guidez, François-Xavier Gros, Emmanuel Bachy, Pascale Cony-Makhoul, Steven P Treon, Alain Jacques Delmer, Ran Reshef, Steven Le Gouill, Jorge J. Castillo, Roch Houot

Blood (2023) 142 (Supplement 1): 616.

https://doi.org/10.1182/blood-2023-173988

Published: 2023

Journal Articles

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 228.

https://doi.org/10.1182/blood-2023-185035

Published: 2023

Journal Articles

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

Gilles Crochet, Couturier Audrey, Emmanuel Bachy, Thomas Gastinne, Guillaume Cartron, Tom Fradon, Romain Gounot, Cristina Castilla-LLorente, Clementine Sarkozy, Vincent Camus, Stéphanie Guidez, Adrien Chauchet, Eric Deconinck, Krimo Bouabdallah, Franck Morschhauser, Roch Houot

Blood (2022) 140 (Supplement 1): 4639–4641.

https://doi.org/10.1182/blood-2022-162594

Published: 2022

Journal Articles

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Blood (2022) 140 (Supplement 1): 2302–2305.

https://doi.org/10.1182/blood-2022-165217

Published: 2022

Journal Articles

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2021-154729

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: A multicentric retrospective study

Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with chronic lymphocytic leukemia

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only